Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Pharmacol., 14 November 2025

Sec. Pharmacology of Anti-Cancer Drugs

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1730637

Correction: Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single–center retrospective cohort study

This article is a correction to:

  1. Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single–center retrospective cohort study

    1. Read original article
Ying Liu&#x;Ying Liu1†Taoyan Lin,&#x;Taoyan Lin1,2†Boxin Zhao,Boxin Zhao1,2Yilei Li, Yilei Li1,2*Ping Zheng, Ping Zheng1,2*
  • 1Department Pharmacy, Institute Nanfang Hospital, Organization Southern Medical University, Guangzhou, China
  • 2Department Clinical Pharmacy Center, Institute Nanfang Hospital, Organization Southern Medical University, Guangzhou, China

A Correction on
Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single–center retrospective cohort study

by Liu Y, Lin T, Zhao B, Li Y and Zheng P (2025). Front. Pharmacol. 16:1676800. doi: 10.3389/fphar.2025.1676800

The funding statement was erroneously written as “This study is supported by the GuangDong Pharmaceutical Association (Nos. 2023JZ04, 2024A02036, 2025HJB01006, 2025A02036) to YL.” This has now been corrected to the following: “This study is supported by the GuangDong Pharmaceutical Association (No. 2024A02036 and 2025HJB01006 to YTL; No. 2023JZ04 and 2025A02036 to PZ).”

The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: nilotinib, chronic myeloid leukemia, plasma concentration, TDM, efficacy, safety

Citation: Liu Y, Lin T, Zhao B, Li Y and Zheng P (2025) Correction: Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single–center retrospective cohort study. Front. Pharmacol. 16:1730637. doi: 10.3389/fphar.2025.1730637

Received: 23 October 2025; Accepted: 28 October 2025;
Published: 14 November 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Liu, Lin, Zhao, Li and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ping Zheng, enBtMzIxQDEyNi5jb20=; Yilei Li, bGl5aWxlaTE5NzVAMTYzLmNvbQ==

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.